Home / Health / Drug Pioneer John Lewis's Legacy: Saving Millions

Drug Pioneer John Lewis's Legacy: Saving Millions

Summary

  • Lewis developed buprenorphine as an alternative painkiller and addiction treatment.
  • His work at Reckitt & Colman led to treatments used by millions globally.
  • He received international recognition, including congratulations from royalty and a US president.
Drug Pioneer John Lewis's Legacy: Saving Millions

John Lewis, who passed away at 92, was a pivotal figure in pharmaceutical research, renowned for his lead role in developing buprenorphine. This drug has since become a successful alternative to morphine for pain management and a critical treatment for opioid addiction, impacting millions globally.

Lewis's groundbreaking work primarily occurred during his tenure as research and development director at Reckitt & Colman pharmaceuticals and later at Bristol University. His dedication to psychopharmacology research continued independently, culminating in his retirement in 2018. His contributions were acknowledged with prestigious awards and letters of congratulations from Queen Elizabeth II and President Bill Clinton.

The development of buprenorphine, alongside pharmacologist Alan Cowan, is considered Lewis's greatest scientific achievement. This innovation provided a vital treatment option for opioid dependence, particularly heroin addiction, and has become a leading medication for opioid substitution therapy worldwide.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
John Lewis was a research scientist who played a leading role in developing buprenorphine, a medication for pain and opioid addiction.
Buprenorphine is used as a painkiller after operations and as a treatment for opioid drug addiction, offering an alternative to methadone.
John Lewis conducted his research primarily at Reckitt & Colman pharmaceuticals, Bristol University, and Bath University.

Read more news on